Navigation Links
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Date:8/5/2009

both recurring and non-recurring, that Shire's management believes are not related to the core performance of Shire's business. A list of these items can be found on pages 26-27.

PRODUCT LAUNCHES

Subject to obtaining the relevant regulatory/governmental approvals, product launches planned over the next two years include:

    - MEZAVANT for the treatment of ulcerative colitis; launches will
      continue in certain EU and RoW countries in 2009 and 2010;

    - FIRAZYR for the symptomatic treatment of acute attacks of HAE; launches
      will continue in certain European and Latin American countries during
      2009 and 2010;

    - INTUNIV for the treatment of ADHD in children and adolescents in the
      US in the fourth quarter of 2009;

    - EQUASYM(R) for the treatment of ADHD; launches will continue in certain
      EU countries during 2009 and 2010;

    - DAYTRANA(R) for the treatment of ADHD in adolescents in the US in 2010;

    - Velaglucerase alfa for the treatment of Gaucher disease in the US and
      the EU in 2010; and

    - VYVANSE for the treatment of ADHD, in ex-US and ex-EU regions starting
      in 2010, and in the EU in 2011.

DIVIDEND

In respect of the six months ended June 30, 2009, the Board resolved to pay an interim dividend of 2.147 US cents per ordinary share (2008: 2.147 US cents per share).

Dividend payments will be made in Pounds Sterling to Ordinary shareholders and in US Dollars to holders of American Depository Shares ("ADS"). A dividend of 1.302 pence per ordinary share (2008: 1.085 pence) and 6.441 US cents per ADS (2008: 6.441 US cents) will be paid on October 8, 2009 to persons whose names appear on the register of members of the Company at the close of business on September 11, 2009.

    Additional Information
    The following additional information is included in this press release:

      
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines (NASDAQ: ... its initial public offering of 9,367,708 shares of ... $18.00 per share, including shares of common stock ... of their option to purchase additional shares. The ... Blueprint Medicines were approximately $168.6 million, before underwriting discounts ...
(Date:5/5/2015)... 2015 VetStem Biopharma, proudly announces ... Jeffrey Schaffer, DVM, as Director of Veterinary Professional ... of experience in the veterinary regenerative medicine field ... our veterinarian lead organization”. Dr. Alexis Nahama, ... will be responsible for all technical activities in ...
(Date:5/5/2015)... Israel , May 5, 2015  Tikcro ... Company was approved to continue trading on OTCQB  ... OTCQB Marketplace allows for a continuous ... broker-dealers. Investors can have real-time quotes and market ... The OTCQB Marketplace includes U.S. and ...
(Date:5/5/2015)... NEW YORK , May 5, 2015 /PRNewswire/ ... today announced that Andrew Gengos , President and ... on May 7, 2015. DATE:  Thursday, May ... LINK:  http://VirtualInvestorConferences.com > click the ... will be a live, interactive online event where ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2
... 11 Schering-Plough,Corporation (NYSE: SGP ) today announced ... of a New Drug Application (NDA) for ZEGERID(R),(omeprazole/sodium bicarbonate) ... a branded over-the-counter (OTC) product to treat frequent,heartburn., ... license agreement with,Santarus, Inc. of San Diego, Calif., which ...
... analysis affordable and accessible to all researchers, ... today that Harvard Medical School and the University ... Program. Each University,purchased access to whole genome human ... Consortium and distributed by Open Biosystems., (Logo: ...
... China,Bionanometer Industries Corporation (Pink Sheets: CBIU), a ... signed an agreement to,establish long-term strategic cooperative ... Guangzhou LGLY Advertising LTD is China,s top ... and is well-known for its core senior ...
Cached Biology Technology:Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 2Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 3Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina 2CBIU Signs Agreement with LGLY Advertising LTD 2
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... Deamer began studying the origin of life in the early ... had a major influence on scientific understanding of how life ... (UC Press, June 2011), Deamer presents a personal history of ... and accessible overview of research into life,s beginnings. ...
... of the 2010 Nobel Prize in Chemistry, will be ... Chemistry and Engineering Conference, June 21-23, in Washington, D.C. ... Hilton Hotel, just two blocks north of the White ... around the world, is sponsored by the American Chemical ...
... 2011) New research suggests an effective recovery drink ... Grabbing lowfat chocolate milk after a tough workout helped ... advantage, according to three new studies presented at the ... Journal of Strength and Conditioning Research this ...
Cached Biology News:Biochemist David Deamer explores how life began in new book, 'First Life' 2Nobel Laureate to speak at American Chemical Society green chemistry conference 2New research: Post-exercise recovery advantages of lowfat chocolate milk 2